Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 1 of 1 (100%) have an AI response strategy ready
Northsea Therapeutics B V has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is currently being processed within 1 distinct art unit, reflecting a focus for the company's active patent applications. The presence of 1 pending office action suggests a specific intellectual property portfolio.
The prosecution is being handled by 1 distinct examiner, SCHMIDT, IZABELA MARIA. As the busiest examiner for the company, SCHMIDT, IZABELA MARIA is responsible for 1 busiest examiner pending action. This concentration means that the company's immediate success in the patent office depends on the review of this 1 distinct examiner.
For those managing the portfolio, the 1 busiest examiner pending action in Biotechnology & Pharmaceuticals is the priority. Because there is 1 distinct examiner involved, the strategy can be tailored specifically to the feedback from SCHMIDT, IZABELA MARIA. The 1 busiest examiner pending action represents the company's current prosecution challenges.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMIDT, IZABELA MARIA | 1 | 65.3% | +42.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18258620 | COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | SCHMIDT, IZABELA MARIA | 8d overdue |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18258620 | COMBINATION THERAPIES COMPRISING OXYGEN-CONTAINING STRUCTURALLY ENHANCED FATTY ACIDS FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS | SCHMIDT, IZABELA MARIA | 1621 | §102Other | Non-Final OA | 8d overdue | AI Ready | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial